Details of the Drug Combination

General Information of Drug Combination (ID: DCWH9M9)

Drug Combination Name
Gefitinib Mifepristone
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs Gefitinib   DM15F0X Mifepristone   DMGZQEF
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SU-DIPG-XIII
Zero Interaction Potency (ZIP) Score: 5.04
Bliss Independence Score: 11.874
Loewe Additivity Score: 0.611
LHighest Single Agent (HSA) Score: 0.998

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Gefitinib
Disease Entry ICD 11 Status REF
Colon adenocarcinoma N.A. Approved [2]
Glioblastoma 2A00 Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Rectal adenocarcinoma 2B92 Approved [2]
Rectum mucinous adenocarcinoma N.A. Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Head and neck cancer 2D42 Phase 3 [3]
Urethral cancer 2C93 Phase 2 [3]
Colon cancer 2B90.Z Investigative [2]
Colon mucinous adenocarcinoma N.A. Investigative [2]
Gefitinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [10]
------------------------------------------------------------------------------------
Gefitinib Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [12]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [13]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [13]
------------------------------------------------------------------------------------
Gefitinib Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [14]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [15]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [14]
------------------------------------------------------------------------------------
Gefitinib Interacts with 103 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases ADR [16]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Response To Substance [17]
Sulfhydryl oxidase 1 (QSOX1) OT4ZPK4P QSOX1_HUMAN Increases Expression [18]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G) OT8V1J4M GA45G_HUMAN Decreases Expression [18]
Interferon alpha-inducible protein 6 (IFI6) OTWOOAM4 IFI6_HUMAN Decreases Expression [18]
Fibroblast growth factor 6 (FGF6) OTRJ679P FGF6_HUMAN Increases Expression [18]
Ski oncogene (SKI) OT4KJ8F6 SKI_HUMAN Increases Expression [18]
Erythropoietin receptor (EPOR) OTUIOEU3 EPOR_HUMAN Increases Expression [18]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Decreases Expression [18]
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) OTDS2EAR TNR1B_HUMAN Decreases Expression [18]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [18]
Cytochrome P450 2F1 (CYP2F1) OTY3HJH1 CP2F1_HUMAN Decreases Expression [18]
Replication protein A 70 kDa DNA-binding subunit (RPA1) OT76POLP RFA1_HUMAN Increases Expression [18]
Adenosine receptor A1 (ADORA1) OTI7X39E AA1R_HUMAN Decreases Expression [18]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Decreases Expression [18]
DNA mismatch repair protein Mlh1 (MLH1) OTG5XDD8 MLH1_HUMAN Decreases Expression [18]
Glycine--tRNA ligase (GARS1) OT5B6R9Y GARS_HUMAN Increases Expression [18]
Epidermal growth factor receptor substrate 15 (EPS15) OT7NPP8U EPS15_HUMAN Increases Expression [18]
Neuronal pentraxin-2 (NPTX2) OT3SSJDP NPTX2_HUMAN Decreases Expression [18]
Leptin receptor (LEPR) OT9H7G0C LEPR_HUMAN Decreases Expression [18]
Neural retina-specific leucine zipper protein (NRL) OT65MFKQ NRL_HUMAN Decreases Expression [18]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 (GNB2) OT3JPRCQ GBB2_HUMAN Decreases Expression [18]
Retinal guanylyl cyclase 1 (GUCY2D) OT81UJI0 GUC2D_HUMAN Decreases Expression [18]
Cell growth regulator with RING finger domain protein 1 (CGRRF1) OTLMNRCL CGRF1_HUMAN Increases Expression [18]
Dual specificity protein phosphatase 9 (DUSP9) OTZZWEQL DUS9_HUMAN Decreases Expression [18]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [19]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [20]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Decreases Expression [20]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [20]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Expression [21]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [22]
Ubiquitin-like modifier-activating enzyme ATG7 (ATG7) OTVT4YA1 ATG7_HUMAN Increases Expression [23]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [24]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [6]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [25]
HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1) OTRGGIFP DRB1_HUMAN Affects Expression [26]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Phosphorylation [27]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Decreases Phosphorylation [28]
HLA class II histocompatibility antigen, DO alpha chain (HLA-DOA) OTZE5Q7R DOA_HUMAN Affects Expression [26]
Heat shock protein HSP 90-alpha (HSP90AA1) OTLG1WPK HS90A_HUMAN Increases Secretion [25]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Increases Phosphorylation [29]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Increases Secretion [25]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [30]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Increases Secretion [25]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Secretion [31]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Expression [6]
Platelet endothelial cell adhesion molecule (PECAM1) OTXOM4D9 PECA1_HUMAN Decreases Expression [6]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Decreases Phosphorylation [23]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [32]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [17]
DnaJ homolog subfamily B member 1 (DNAJB1) OTCOSEVH DNJB1_HUMAN Increases Secretion [25]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Expression [33]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Expression [33]
Caspase-1 (CASP1) OTZ3YQFU CASP1_HUMAN Increases Activity [25]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [17]
HLA class I histocompatibility antigen, alpha chain F (HLA-F) OT76CM19 HLAF_HUMAN Affects Expression [26]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [34]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [22]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Phosphorylation [23]
Cyclin-dependent kinase 4 inhibitor B (CDKN2B) OTAG24N1 CDN2B_HUMAN Increases Expression [24]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Decreases Phosphorylation [6]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [17]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Response To Substance [35]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [30]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [21]
Caveolin-1 (CAV1) OTEZUR1L CAV1_HUMAN Increases Expression [33]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Decreases Expression [36]
Kelch-like ECH-associated protein 1 (KEAP1) OTFHOD0C KEAP1_HUMAN Increases Expression [37]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Cleavage [35]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [38]
MHC class I polypeptide-related sequence B (MICB) OTS2DVDW MICB_HUMAN Increases Expression [39]
MHC class I polypeptide-related sequence A (MICA) OTPEIEAR MICA_HUMAN Increases Expression [39]
Estrogen receptor beta (ESR2) OTXNR2WQ ESR2_HUMAN Increases Expression [40]
Serine protease HTRA1 (HTRA1) OTR8ACBF HTRA1_HUMAN Increases Expression [41]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Affects Expression [26]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Increases Expression [23]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [42]
MARVEL domain-containing protein 1 (MARVELD1) OT5CPOJE MALD1_HUMAN Decreases Response To Substance [43]
GTPase KRas (KRAS) OT78QCN8 RASK_HUMAN Decreases Response To Substance [44]
Zinc finger protein SNAI2 (SNAI2) OT7Y8EJ2 SNAI2_HUMAN Affects Response To Substance [45]
Membrane-associated progesterone receptor component 1 (PGRMC1) OTBE6WAC PGRC1_HUMAN Decreases Response To Substance [46]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Response To Substance [47]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Affects Response To Substance [48]
RNA-binding protein 7 (RBM7) OTFIWTMF RBM7_HUMAN Affects Response To Substance [48]
Cell death regulator Aven (AVEN) OTGIN5YK AVEN_HUMAN Affects Response To Substance [48]
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Increases Response To Substance [49]
Phospholipase B-like 1 (PLBD1) OTHYEB4W PLBL1_HUMAN Affects Response To Substance [48]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Response To Substance [50]
Securin (PTTG1) OTIMYS4W PTTG1_HUMAN Decreases Response To Substance [30]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Decreases Response To Substance [48]
Pleckstrin homology-like domain family A member 2 (PHLDA2) OTMV9DPP PHLA2_HUMAN Affects Response To Substance [48]
Aurora kinase A (AURKA) OTMX0HYT AURKA_HUMAN Decreases Response To Substance [50]
DNA excision repair protein ERCC-1 (ERCC1) OTNPYQHI ERCC1_HUMAN Affects Response To Substance [9]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Response To Substance [51]
Ceramide transfer protein (CERT1) OTNUCNHX CERT_HUMAN Affects Response To Substance [48]
DNA repair protein RAD51 homolog 1 (RAD51) OTNVWGC1 RAD51_HUMAN Affects Response To Substance [52]
Oncostatin-M-specific receptor subunit beta (OSMR) OTORWHPL OSMR_HUMAN Affects Response To Substance [48]
Protransforming growth factor alpha (TGFA) OTPD1LL9 TGFA_HUMAN Decreases Response To Substance [53]
Dual specificity protein phosphatase 3 (DUSP3) OTPJX9B4 DUS3_HUMAN Affects Response To Substance [48]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Response To Substance [50]
Pericentrin (PCNT) OTW4Z65J PCNT_HUMAN Decreases Response To Substance [46]
Coronin-1C (CORO1C) OTXDF9T3 COR1C_HUMAN Affects Response To Substance [48]
Ribonucleoside-diphosphate reductase large subunit (RRM1) OTXGQOR9 RIR1_HUMAN Affects Response To Substance [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 103 DOT(s)
Indication(s) of Mifepristone
Disease Entry ICD 11 Status REF
Cushing disease 5A70 Approved [4]
Mifepristone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Modulator [56]
------------------------------------------------------------------------------------
Mifepristone Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [57]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [58]
------------------------------------------------------------------------------------
Mifepristone Interacts with 228 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [59]
Pro-neuropeptide Y (NPY) OT4ICV3P NPY_HUMAN Increases ADR [60]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Increases Expression [61]
Frizzled-9 (FZD9) OTTZ9MKK FZD9_HUMAN Increases Expression [54]
Forkhead box protein N3 (FOXN3) OTOJYJZP FOXN3_HUMAN Increases Expression [54]
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2) OTKOZRZP PLOD2_HUMAN Increases Expression [54]
Actin-binding LIM protein 1 (ABLIM1) OTHXEK3E ABLM1_HUMAN Increases Expression [54]
Ectoderm-neural cortex protein 1 (ENC1) OTJEUB6U ENC1_HUMAN Increases Expression [54]
Histone-lysine N-methyltransferase 2D (KMT2D) OTTVHCLY KMT2D_HUMAN Decreases Expression [54]
17-beta-hydroxysteroid dehydrogenase type 6 (HSD17B6) OTSB55D2 H17B6_HUMAN Decreases Expression [54]
Branched-chain-amino-acid aminotransferase, mitochondrial (BCAT2) OT8L6EGI BCAT2_HUMAN Decreases Expression [54]
Calpain-5 (CAPN5) OTQ8QM7K CAN5_HUMAN Decreases Expression [54]
Leucine-rich repeat transmembrane protein FLRT2 (FLRT2) OTGD8TID FLRT2_HUMAN Decreases Expression [54]
Septin-4 (SEPTIN4) OTD16B30 SEPT4_HUMAN Decreases Expression [54]
Cationic amino acid transporter 4 (SLC7A4) OTAVC6QS CTR4_HUMAN Decreases Expression [54]
Proline dehydrogenase 1, mitochondrial (PRODH) OT7SQ1C7 PROD_HUMAN Decreases Expression [54]
Synaptogyrin-1 (SYNGR1) OT0MBUK5 SNG1_HUMAN Decreases Expression [54]
C-X-C motif chemokine 13 (CXCL13) OT2AT4N8 CXL13_HUMAN Decreases Expression [54]
Frizzled-6 (FZD6) OTBCPII8 FZD6_HUMAN Increases Expression [54]
Sushi repeat-containing protein SRPX2 (SRPX2) OT6A63TX SRPX2_HUMAN Increases Expression [54]
Sorting nexin-2 (SNX2) OT889MQA SNX2_HUMAN Increases Expression [54]
P antigen family member 4 (PAGE4) OT2VLWT0 PAGE4_HUMAN Decreases Expression [54]
Slit homolog 3 protein (SLIT3) OTU8MKEU SLIT3_HUMAN Decreases Expression [54]
Large neutral amino acids transporter small subunit 3 (SLC43A1) OTQJQY3S LAT3_HUMAN Decreases Expression [54]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Decreases Expression [54]
E3 ubiquitin-protein ligase NEURL1 (NEURL1) OT2C4P70 NEUL1_HUMAN Increases Expression [54]
Cystatin-F (CST7) OTQWZUVQ CYTF_HUMAN Decreases Expression [54]
Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3 (B3GAT3) OTDSN5XF B3GA3_HUMAN Decreases Expression [54]
Myelin protein zero-like protein 1 (MPZL1) OTJSUUHR MPZL1_HUMAN Decreases Expression [54]
Supervillin (SVIL) OTWQQ1WK SVIL_HUMAN Increases Expression [54]
Follistatin-related protein 3 (FSTL3) OT75489W FSTL3_HUMAN Decreases Expression [54]
Protein LDOC1 (LDOC1) OTWZH4O9 LDOC1_HUMAN Decreases Expression [54]
Coagulation factor XIII A chain (F13A1) OTO8O184 F13A_HUMAN Increases Expression [54]
Tissue-type plasminogen activator (PLAT) OTQPDNAB TPA_HUMAN Increases Expression [54]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [54]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Increases Expression [54]
Collagen alpha-1(II) chain (COL2A1) OT5E59C8 CO2A1_HUMAN Decreases Expression [54]
Apolipoprotein C-I (APOC1) OTA58CED APOC1_HUMAN Decreases Expression [54]
Annexin A1 (ANXA1) OT5OFDJC ANXA1_HUMAN Increases Expression [54]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Decreases Expression [54]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Increases Expression [54]
Protein S100-A6 (S100A6) OTHHPZQ8 S10A6_HUMAN Decreases Expression [54]
Tyrosine 3-monooxygenase (TH) OT6ZORKP TY3H_HUMAN Decreases Expression [54]
Decorin (DCN) OTWLJL7K PGS2_HUMAN Increases Expression [54]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Increases Expression [54]
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Increases Expression [54]
Glutathione S-transferase A1 (GSTA1) OTA7K5XA GSTA1_HUMAN Increases Expression [54]
Inhibin beta A chain (INHBA) OTSP64PQ INHBA_HUMAN Increases Expression [54]
Matrilysin (MMP7) OTVT3SEJ MMP7_HUMAN Increases Expression [54]
Stromelysin-2 (MMP10) OTJDWW8Q MMP10_HUMAN Increases Expression [54]
Growth-regulated alpha protein (CXCL1) OT3WCTZV GROA_HUMAN Decreases Expression [54]
Fructose-bisphosphate aldolase C (ALDOC) OTEC13I5 ALDOC_HUMAN Decreases Expression [54]
Glutathione S-transferase theta-2 (GSTT2) OTANW3TJ GST2_HUMAN Decreases Expression [54]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Decreases Expression [54]
Thyroid hormone receptor alpha (THRA) OTKRLVD7 THA_HUMAN Decreases Expression [54]
Thyroid hormone receptor beta (THRB) OTBBIRHZ THB_HUMAN Increases Expression [54]
Pyruvate carboxylase, mitochondrial (PC) OT6O0V51 PYC_HUMAN Decreases Expression [54]
Creatine kinase B-type (CKB) OTUCKOTT KCRB_HUMAN Decreases Expression [54]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [54]
Cytochrome P450 4B1 (CYP4B1) OTJP46CB CP4B1_HUMAN Decreases Expression [54]
Retinoic acid receptor gamma (RARG) OT8LHMDH RARG_HUMAN Decreases Expression [54]
HLA class II histocompatibility antigen, DO beta chain (HLA-DOB) OTKADDUB DOB_HUMAN Decreases Expression [54]
Aminopeptidase N (ANPEP) OTP3WYFD AMPN_HUMAN Decreases Expression [54]
15-hydroxyprostaglandin dehydrogenase (HPGD) OTYZI6JB PGDH_HUMAN Decreases Expression [54]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Decreases Expression [54]
Platelet glycoprotein 4 (CD36) OT5CZWKY CD36_HUMAN Decreases Expression [54]
Fumarylacetoacetase (FAH) OTGZA1YR FAAA_HUMAN Decreases Expression [54]
Gap junction alpha-1 protein (GJA1) OTT94MKL CXA1_HUMAN Increases Expression [54]
Insulin-like growth factor-binding protein 3 (IGFBP3) OTIX63TX IBP3_HUMAN Increases Expression [54]
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) OT2D9DOV TNR1A_HUMAN Increases Expression [54]
Fibulin-1 (FBLN1) OT5MHHOP FBLN1_HUMAN Decreases Expression [54]
Prostaglandin G/H synthase 1 (PTGS1) OTHCRLEC PGH1_HUMAN Decreases Expression [54]
Integrin alpha-6 (ITGA6) OT3FA39C ITA6_HUMAN Increases Expression [54]
Laminin subunit alpha-2 (LAMA2) OTFROQWE LAMA2_HUMAN Decreases Expression [54]
Endothelin receptor type B (EDNRB) OTLLZV3P EDNRB_HUMAN Increases Expression [54]
Insulin-like growth factor-binding protein 5 (IGFBP5) OTRE5V0C IBP5_HUMAN Decreases Expression [54]
Atypical chemokine receptor 3 (ACKR3) OTA6GA4F ACKR3_HUMAN Decreases Expression [54]
Collagen alpha-5(IV) chain (COL4A5) OTHG60RE CO4A5_HUMAN Decreases Expression [54]
ER lumen protein-retaining receptor 2 (KDELR2) OT9QW7Q0 ERD22_HUMAN Increases Expression [54]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Increases Expression [54]
Pigment epithelium-derived factor (SERPINF1) OTWZH98J PEDF_HUMAN Decreases Expression [54]
Prostaglandin-H2 D-isomerase (PTGDS) OT71NN7C PTGDS_HUMAN Decreases Expression [54]
5-hydroxytryptamine receptor 2B (HTR2B) OTM1AD9J 5HT2B_HUMAN Increases Expression [54]
Glutamate receptor 1 (GRIA1) OT85LOCJ GRIA1_HUMAN Decreases Expression [54]
C-X-C motif chemokine 5 (CXCL5) OTZOUPCA CXCL5_HUMAN Increases Expression [54]
Prostacyclin receptor (PTGIR) OTWTABYM PI2R_HUMAN Increases Expression [54]
Small ribosomal subunit protein eS10 (RPS10) OTE3VSAH RS10_HUMAN Increases Expression [54]
Microtubule-associated protein 1B (MAP1B) OTVXW089 MAP1B_HUMAN Increases Expression [54]
Stromal cell-derived factor 1 (CXCL12) OT2QX5LL SDF1_HUMAN Increases Expression [54]
Transcription factor SOX-9 (SOX9) OTVDJFGN SOX9_HUMAN Increases Expression [54]
Heat shock 70 kDa protein 13 (HSPA13) OTYXMC4G HSP13_HUMAN Increases Expression [54]
DNA polymerase delta subunit 2 (POLD2) OTBNASP6 DPOD2_HUMAN Decreases Expression [54]
MARCKS-related protein (MARCKSL1) OT13J2FM MRP_HUMAN Increases Expression [54]
Steroidogenic acute regulatory protein, mitochondrial (STAR) OTFEZ5AI STAR_HUMAN Decreases Expression [54]
ADP-ribosylation factor-like protein 4D (ARL4D) OTG5I3KU ARL4D_HUMAN Decreases Expression [54]
Matrix metalloproteinase-14 (MMP14) OT9C197Z MMP14_HUMAN Increases Expression [54]
Matrix metalloproteinase-16 (MMP16) OTSFQ2BJ MMP16_HUMAN Increases Expression [54]
RNA-binding protein Nova-1 (NOVA1) OT6A9KHY NOVA1_HUMAN Increases Expression [54]
Lumican (LUM) OTSRC874 LUM_HUMAN Increases Expression [54]
ATP-citrate synthase (ACLY) OTRL9ZRP ACLY_HUMAN Increases Expression [54]
Cadherin-11 (CDH11) OTIZKPTF CAD11_HUMAN Increases Expression [54]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Expression [54]
Sestrin-3 (SESN3) OTJRY1Y5 SESN3_HUMAN Increases Expression [54]
Actin, cytoplasmic 1 (ACTB) OT1MCP2F ACTB_HUMAN Decreases Expression [54]
Ras-related protein Rap-1b (RAP1B) OTHEIIMM RAP1B_HUMAN Increases Expression [54]
26S proteasome regulatory subunit 10B (PSMC6) OTG8997V PRS10_HUMAN Increases Expression [54]
Large ribosomal subunit protein eL39 (RPL39) OTL8TZHQ RL39_HUMAN Increases Expression [54]
Contactin-associated protein 1 (CNTNAP1) OT5Y03EU CNTP1_HUMAN Decreases Expression [54]
Fractalkine (CX3CL1) OTPLGI0E X3CL1_HUMAN Increases Expression [54]
Sushi repeat-containing protein SRPX (SRPX) OT5B9LXS SRPX_HUMAN Decreases Expression [54]
C-C motif chemokine 8 (CCL8) OTCTWYN8 CCL8_HUMAN Decreases Expression [54]
Rho-related GTP-binding protein RhoG (RHOG) OTJ7J1WA RHOG_HUMAN Decreases Expression [54]
Small EDRK-rich factor 2 (SERF2) OTZQDYCZ SERF2_HUMAN Increases Expression [54]
Norrin (NDP) OTGDJ4US NDP_HUMAN Decreases Expression [54]
Angiopoietin-1 receptor (TEK) OT78YN57 TIE2_HUMAN Increases Expression [54]
Tyrosine-protein kinase BTK (BTK) OTG3CDVK BTK_HUMAN Increases Expression [54]
Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit alpha (PPP2R3A) OTSK5GFC P2R3A_HUMAN Increases Expression [54]
Early activation antigen CD69 (CD69) OTGJHSVP CD69_HUMAN Increases Expression [54]
Tight junction protein ZO-1 (TJP1) OTBDCUPK ZO1_HUMAN Increases Expression [54]
Sperm-associated antigen 1 (SPAG1) OT29JZKW SPAG1_HUMAN Increases Expression [54]
ATP-binding cassette sub-family C member 8 (ABCC8) OTCWQ54I ABCC8_HUMAN Decreases Expression [54]
Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 (AIMP1) OTTA5C3U AIMP1_HUMAN Increases Expression [54]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 (BNIP2) OTVZD4H6 BNIP2_HUMAN Increases Expression [54]
Metastasis-associated protein MTA1 (MTA1) OTBHW3S9 MTA1_HUMAN Decreases Expression [54]
Phospholipase D1 (PLD1) OTMVUKW6 PLD1_HUMAN Increases Expression [54]
Laminin subunit gamma-2 (LAMC2) OTJMTM72 LAMC2_HUMAN Increases Expression [54]
Collagen alpha-6(IV) chain (COL4A6) OTUREU5Z CO4A6_HUMAN Decreases Expression [54]
Interleukin-13 receptor subunit alpha-2 (IL13RA2) OTPC2G0X I13R2_HUMAN Increases Expression [54]
ADP-ribosylation factor-like protein 6-interacting protein 1 (ARL6IP1) OT536XAV AR6P1_HUMAN Increases Expression [54]
Receptor-type tyrosine-protein phosphatase kappa (PTPRK) OTAP5AT3 PTPRK_HUMAN Increases Expression [54]
P2Y purinoceptor 14 (P2RY14) OTDGZKED P2Y14_HUMAN Increases Expression [54]
Monocyte to macrophage differentiation factor (MMD) OTB5I4OC PAQRB_HUMAN Increases Expression [54]
TSC22 domain family protein 1 (TSC22D1) OTN4GFWD T22D1_HUMAN Increases Expression [54]
Adipogenesis regulatory factor (ADIRF) OTTJP8D4 ADIRF_HUMAN Decreases Expression [54]
Mitogen-activated protein kinase 6 (MAPK6) OTDDNF3Q MK06_HUMAN Increases Expression [54]
Laminin subunit alpha-3 (LAMA3) OTFME7HT LAMA3_HUMAN Decreases Expression [54]
Centrosomal protein kizuna (KIZ) OT5VCKSM KIZ_HUMAN Increases Expression [54]
Carboxypeptidase Z (CPZ) OT5HUR28 CBPZ_HUMAN Increases Expression [54]
F-box only protein 46 (FBXO46) OT773EPG FBX46_HUMAN Decreases Expression [54]
Plexin domain-containing protein 2 (PLXDC2) OTS1FUV6 PXDC2_HUMAN Increases Expression [54]
Acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase (B3GNT6) OTAX8BNJ B3GN6_HUMAN Decreases Expression [54]
Protein mono-ADP-ribosyltransferase TIPARP (TIPARP) OTZ4BG4B PARPT_HUMAN Decreases Expression [54]
Kinesin-like protein KIF27 (KIF27) OTV70I2Q KIF27_HUMAN Increases Expression [54]
Osteopetrosis-associated transmembrane protein 1 (OSTM1) OTKNJDH7 OSTM1_HUMAN Increases Expression [54]
Membrane progestin receptor alpha (PAQR7) OTIWX5AM PAQR7_HUMAN Decreases Expression [54]
Secreted frizzled-related protein 1 (SFRP1) OT0U9G41 SFRP1_HUMAN Increases Expression [54]
RB1-inducible coiled-coil protein 1 (RB1CC1) OTZK8PFX RBCC1_HUMAN Increases Expression [54]
Protein phosphatase 1 regulatory subunit 1C (PPP1R1C) OTVH6BND PPR1C_HUMAN Increases Expression [54]
Kelch-like protein 6 (KLHL6) OTLDECOX KLHL6_HUMAN Increases Expression [54]
C-type lectin domain family 2 member B (CLEC2B) OT0W0M0L CLC2B_HUMAN Increases Expression [54]
(3R)-3-hydroxyacyl-CoA dehydrogenase (HSD17B8) OTX1DWEF DHB8_HUMAN Decreases Expression [54]
Tribbles homolog 2 (TRIB2) OTHSX3MX TRIB2_HUMAN Increases Expression [54]
Histone deacetylase 2 (HDAC2) OTUYVFKN HDAC2_HUMAN Increases Expression [54]
Type II iodothyronine deiodinase (DIO2) OTGPNSLH IOD2_HUMAN Increases Expression [54]
Stathmin-2 (STMN2) OT0FUHLH STMN2_HUMAN Increases Expression [54]
Seipin (BSCL2) OT73V6Y4 BSCL2_HUMAN Decreases Expression [54]
Receptor expression-enhancing protein 6 (REEP6) OTY4FPO8 REEP6_HUMAN Decreases Expression [54]
Mannose-1-phosphate guanyltransferase alpha (GMPPA) OTADC03N GMPPA_HUMAN Decreases Expression [54]
Mastermind-like protein 3 (MAML3) OTZFV53Z MAML3_HUMAN Increases Expression [54]
Translocation protein SEC62 (SEC62) OTCWEL5F SEC62_HUMAN Increases Expression [54]
Mitochondrial import inner membrane translocase subunit Tim17-A (TIMM17A) OTVFRL8G TI17A_HUMAN Increases Expression [54]
C-C motif chemokine 13 (CCL13) OTNX0JD0 CCL13_HUMAN Decreases Expression [54]
SH3-containing GRB2-like protein 3-interacting protein 1 (SGIP1) OTQW6R3Z SGIP1_HUMAN Increases Expression [54]
Receptor expression-enhancing protein 2 (REEP2) OTPCRA5O REEP2_HUMAN Decreases Expression [54]
Latexin (LXN) OTZQ2M6Y LXN_HUMAN Increases Expression [54]
Complement C1q tumor necrosis factor-related protein 6 (C1QTNF6) OT57EPQC C1QT6_HUMAN Increases Expression [54]
Cysteine-rich secretory protein LCCL domain-containing 2 (CRISPLD2) OTVSFHTL CRLD2_HUMAN Decreases Expression [54]
E3 ubiquitin-protein ligase SMURF2 (SMURF2) OT3TRVL7 SMUF2_HUMAN Increases Expression [54]
Netrin-4 (NTN4) OTDRRMP3 NET4_HUMAN Increases Expression [54]
Endothelial cell-specific molecule 1 (ESM1) OT331Y8V ESM1_HUMAN Increases Expression [54]
Exosome complex component RRP46 (EXOSC5) OTADUQ7H EXOS5_HUMAN Decreases Expression [54]
Protein reprimo (RPRM) OTNNBAS1 RPRM_HUMAN Decreases Expression [54]
E3 ubiquitin-protein ligase RNF146 (RNF146) OTE4CO7E RN146_HUMAN Increases Expression [54]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Decreases Expression [54]
CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) OT70T27A CKLF6_HUMAN Increases Expression [54]
Ankyrin repeat domain-containing protein 10 (ANKRD10) OTIZ2VK8 ANR10_HUMAN Increases Expression [54]
LIM and cysteine-rich domains protein 1 (LMCD1) OT3AWE8O LMCD1_HUMAN Decreases Expression [54]
Sentrin-specific protease 1 (SENP1) OTO8J4VV SENP1_HUMAN Increases Expression [54]
Phosphatidylethanolamine N-methyltransferase (PEMT) OTKXRUL9 PEMT_HUMAN Decreases Expression [54]
DnaJ homolog subfamily B member 9 (DNAJB9) OT38EQT6 DNJB9_HUMAN Increases Expression [54]
Alpha-catulin (CTNNAL1) OTESJ6JD CTNL1_HUMAN Increases Expression [54]
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 (ST6GALNAC2) OT9PBQVT SIA7B_HUMAN Increases Expression [54]
Polypyrimidine tract-binding protein 2 (PTBP2) OTF4S7NE PTBP2_HUMAN Increases Expression [54]
Frizzled-4 (FZD4) OTGLZIE0 FZD4_HUMAN Increases Expression [54]
Frizzled-10 (FZD10) OTSAENLT FZD10_HUMAN Increases Expression [54]
Lysosomal thioesterase PPT2 (PPT2) OTD5VJ9A PPT2_HUMAN Increases Expression [54]
Sorting nexin-12 (SNX12) OTARRSWB SNX12_HUMAN Decreases Expression [54]
HIG1 domain family member 1A, mitochondrial (HIGD1A) OTS351DV HIG1A_HUMAN Increases Expression [54]
Band 4.1-like protein 3 (EPB41L3) OTS6CHG2 E41L3_HUMAN Increases Expression [54]
Long-chain fatty acid transport protein 5 (SLC27A5) OT4OK511 S27A5_HUMAN Decreases Expression [54]
Axin-2 (AXIN2) OTRMGQNU AXIN2_HUMAN Increases Expression [54]
Cytosolic Fe-S cluster assembly factor NUBP2 (NUBP2) OTYOTM2B NUBP2_HUMAN Increases Expression [54]
Adhesion G-protein coupled receptor G1 (ADGRG1) OTQBB8NT AGRG1_HUMAN Decreases Expression [54]
Calcineurin-binding protein cabin-1 (CABIN1) OT4G5CIK CABIN_HUMAN Increases Expression [54]
SEC23-interacting protein (SEC23IP) OTTZ0FXP S23IP_HUMAN Increases Expression [54]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Increases Expression [62]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Decreases Expression [63]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [64]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Decreases Expression [65]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [66]
Interleukin-1 receptor-associated kinase-like 2 (IRAK2) OT6Y1QZN IRAK2_HUMAN Decreases Expression [67]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [68]
T-cell surface glycoprotein CD4 (CD4) OT7Z5LNF CD4_HUMAN Decreases Expression [69]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Secretion [70]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Increases Activity [71]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Decreases Activity [72]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [73]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Decreases Activity [74]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [75]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [76]
Brain-derived neurotrophic factor (BDNF) OTLGH7EW BDNF_HUMAN Decreases Expression [77]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Increases Activity [68]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Expression [73]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [78]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [79]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [75]
Cathelicidin antimicrobial peptide (CAMP) OT3Y8011 CAMP_HUMAN Decreases Expression [67]
Forkhead box protein L2 (FOXL2) OTFRQUYL FOXL2_HUMAN Increases Expression [79]
Neutrophil defensin 1 (DEFA1) OT5N1B9B DEF1_HUMAN Decreases Expression [67]
Neutrophil defensin 3 (DEFA3) OTO3N8E1 DEF3_HUMAN Decreases Expression [67]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [76]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [75]
Protein GREB1 (GREB1) OTU6ZA26 GREB1_HUMAN Increases Expression [80]
Progesterone-induced-blocking factor 1 (PIBF1) OTCBT1A1 PIBF1_HUMAN Decreases Expression [67]
Interleukin-1 receptor-associated kinase 4 (IRAK4) OT9JTJWC IRAK4_HUMAN Decreases Expression [67]
Toll-like receptor 7 (TLR7) OT3HZV7Z TLR7_HUMAN Decreases Expression [67]
Semaphorin-3B (SEMA3B) OTCZCPMS SEM3B_HUMAN Increases Response To Substance [81]
Semaphorin-3F (SEMA3F) OTQFMS8S SEM3F_HUMAN Increases Response To Substance [81]
------------------------------------------------------------------------------------
⏷ Show the Full List of 228 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Gefitinib FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2805).
5 Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther. 2008 Mar;7(3):599-606.
6 Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
7 EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J Immunother. 2011 May;34(4):372-81. doi: 10.1097/CJI.0b013e31821b724a.
8 Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo. Arch Toxicol. 2019 Jun;93(6):1555-1571. doi: 10.1007/s00204-019-02453-2. Epub 2019 Apr 16.
9 DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer. 2011 Jul 15;117(14):3201-8. doi: 10.1002/cncr.25863. Epub 2011 Jan 24.
10 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
11 Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009 Aug;68(2):226-37.
12 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
13 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
14 Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
15 Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005;44(10):1067-81.
16 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
17 Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
18 Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
19 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
20 Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
21 Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006 Sep-Oct;26(5A):3387-91.
22 Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
23 EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
24 ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther. 2007 May;6(5):1579-87. doi: 10.1158/1535-7163.MCT-06-0814.
25 Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
26 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
27 Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
28 Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res. 2005 Oct 15;11(20):7480-9. doi: 10.1158/1078-0432.CCR-05-0328.
29 Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007 May 1;13(9):2795-803. doi: 10.1158/1078-0432.CCR-06-2077.
30 Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
31 Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib. Toxicol Lett. 2021 Mar 1;338:1-9. doi: 10.1016/j.toxlet.2020.11.011. Epub 2020 Nov 25.
32 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
33 Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
34 Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
35 The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
36 Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells. Clin Lung Cancer. 2015 Sep;16(5):e55-66. doi: 10.1016/j.cllc.2015.03.006. Epub 2015 Apr 2.
37 Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2016 Nov 1;310:140-149. doi: 10.1016/j.taap.2016.09.010. Epub 2016 Sep 14.
38 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
39 Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. Cancer Sci. 2012 Jan;103(1):7-16. doi: 10.1111/j.1349-7006.2011.02109.x. Epub 2011 Nov 15.
40 Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother. 2010 Feb;64(2):88-92. doi: 10.1016/j.biopha.2009.06.010. Epub 2009 Oct 23.
41 Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023 Aug;43(8):1214-1224. doi: 10.1002/jat.4457. Epub 2023 Mar 11.
42 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
43 Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells. Oncotarget. 2016 Aug 9;7(32):52392-52403.
44 The K-Ras effector p38 MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation. J Biol Chem. 2017 Sep 8;292(36):15070-15079. doi: 10.1074/jbc.M117.779488. Epub 2017 Jul 24.
45 Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1071-9. doi: 10.1164/rccm.201009-1440OC. Epub 2010 Oct 29.
46 Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance. Toxicol Appl Pharmacol. 2015 Nov 1;288(3):359-73. doi: 10.1016/j.taap.2015.08.008. Epub 2015 Aug 20.
47 Induction of CYP1A1 increases gefitinib-induced oxidative stress and apoptosis in A549 cells. Toxicol In Vitro. 2017 Oct;44:36-43.
48 Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 2004 Dec 15;13(24):3029-43. doi: 10.1093/hmg/ddh331. Epub 2004 Oct 20.
49 The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3169-79. doi: 10.1158/1535-7163.MCT-07-0507.
50 Aurora-A promotes gefitinib resistance via a NF-B signaling pathway in p53 knockdown lung cancer cells. Biochem Biophys Res Commun. 2011 Feb 11;405(2):168-72. doi: 10.1016/j.bbrc.2011.01.001. Epub 2011 Jan 7.
51 BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer. Med Oncol. 2011 Jun;28(2):572-7. doi: 10.1007/s12032-010-9470-y. Epub 2010 Mar 17.
52 E3 ubiquitin ligase RNF180 reduces sensitivity of triple-negative breast cancer cells to Gefitinib by downregulating RAD51. Chem Biol Interact. 2022 Feb 25;354:109798. doi: 10.1016/j.cbi.2022.109798. Epub 2022 Jan 6.
53 Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 2005 Oct 15;65(20):9176-84. doi: 10.1158/0008-5472.CAN-05-1556.
54 Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
55 [Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro]. Zhonghua Wai Ke Za Zhi. 2006 Mar 15;44(6):382-5.
56 The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
57 Evaluation of strategies for the assessment of drug-drug interactions involving cytochrome P450 enzymes. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):737-750.
58 Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica. 2006 Apr;36(4):287-99.
59 A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. J Pharmacol Exp Ther. 2002 Oct;303(1):412-23.
60 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
61 Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol. 2006 Jul;70(1):329-39.
62 Effect of the interaction between lipoxygenase pathway and progesterone on the regulation of hydroxysteroid 11-Beta dehydrogenase 2 in cultured human term placental trophoblasts. Biol Reprod. 2008 Mar;78(3):514-20.
63 Influence of progesterone on endometrial nitric oxide synthase expression. Fertil Steril. 2009 May;91(5 Suppl):2157-62.
64 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
65 Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression. Toxicol Appl Pharmacol. 2014 Oct 1;280(1):138-48.
66 Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos. 2003 Nov;31(11):1296-9. doi: 10.1124/dmd.31.11.1296.
67 Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk Lymphoma. 2007 Aug;48(8):1610-7. doi: 10.1080/10428190701471999.
68 Improved assays for xenosensor activation based on reverse transfection. Toxicol In Vitro. 2015 Oct;29(7):1759-65. doi: 10.1016/j.tiv.2015.07.011. Epub 2015 Jul 14.
69 Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells. Immunol Lett. 2010 Jun 15;131(1):24-32. doi: 10.1016/j.imlet.2010.03.009. Epub 2010 Apr 2.
70 [Regulatory effects of mifepristone and progesterone on the secretion of interleukin-6 by cultured eutopic and etopic endometrial cells]. Zhonghua Fu Chan Ke Za Zhi. 2001 Oct;36(10):603-5.
71 Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res. 2004 Aug 1;10(15):5215-25. doi: 10.1158/1078-0432.CCR-03-0637.
72 The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Int J Oncol. 2005 Jun;26(6):1507-15.
73 Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep. 2006 Apr;15(4):743-8.
74 Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4.
75 Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells. Fertil Steril. 2005 Jul;84(1):202-11. doi: 10.1016/j.fertnstert.2005.01.126.
76 Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res. 2007 Jun 1;13(11):3370-9. doi: 10.1158/1078-0432.CCR-07-0164.
77 Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry. 2007 Apr;41(4):321-6. doi: 10.1080/00048670701213211.
78 The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod. 2008 Sep;23(9):2072-9. doi: 10.1093/humrep/den228. Epub 2008 Jun 24.
79 MiR-17-5p/FOXL2/CDKN1B signal programming in oocytes mediates transgenerational inheritance of diminished ovarian reserve in female offspring rats induced by prenatal dexamethasone exposure. Cell Biol Toxicol. 2023 Jun;39(3):867-883. doi: 10.1007/s10565-021-09645-6. Epub 2021 Sep 19.
80 A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
81 Progesterone and 1,25-dihydroxyvitamin D? inhibit endometrial cancer cell growth by upregulating semaphorin 3B and semaphorin 3F. Mol Cancer Res. 2011 Nov;9(11):1479-92. doi: 10.1158/1541-7786.MCR-11-0213. Epub 2011 Sep 20.